Preoperative dexamethasone reduces postoperative pain, nausea and vomiting following mastectomy for breast cancer by Gómez-Hernández, Jorge et al.
RESEARCH ARTICLE Open Access
Preoperative dexamethasone reduces
postoperative pain, nausea and vomiting
following mastectomy for breast cancer
Jorge Gómez-Hernández
1, Alba Lorena Orozco-Alatorre
1, Marisela Domínguez-Contreras
1,
Antonio Oceguera-Villanueva
1, Salvador Gómez-Romo
1, Andrea Socorro Alvarez Villaseñor
2,
Clotilde Fuentes-Orozco
2, Alejandro González-Ojeda
2*
Abstract
Background: Dexamethasone has been reported to reduce postoperative symptoms after different surgical
procedures. We evaluated the efficacy of preoperative dexamethasone in ameliorating postoperative nausea and
vomiting (PONV), and pain after mastectomy.
Methods: In this prospective, double-blind, placebo-controlled study, 70 patients scheduled for mastectomy with
axillary lymph node dissection were analyzed after randomization to treatment with 8 mg intravenous
dexamethasone (n = 35) or placebo (n = 35). All patients underwent standardized procedures for general
anesthesia and surgery. Episodes of PONV and pain score were recorded on a visual analogue scale. Analgesic and
antiemetic requirements were also recorded.
Results: Demographic and medical variables were similar between groups. The incidence of PONV was lower in
the dexamethasone group at the early postoperative evaluation (28.6% vs. 60%; p = 0.02) and at 6 h (17.2% vs.
45.8%; p = 0.03). More patients in the placebo group required additional antiemetic medication (21 vs.8 ;p = 0.01).
Dexamethasone treatment significantly reduced postoperative pain just after surgery (VAS score, 4.54 ± 1.55 vs. 5.83
± 2.00; p = 0.004), at 6 h (3.03 ± 1.20 vs. 4.17 ± 1.24; p < 0.0005) and at 12 h (2.09 ± 0.85 vs. 2.54 ± 0.98; p = 0.04).
Analgesics were required in more patients of the control group (21 vs. 10; p = 0.008). There were no adverse
events, morbidity or mortality.
Conclusions: Preoperative intravenous dexamethasone (8 mg) can significantly reduce the incidence of PONV and
pain in patients undergoing mastectomy with axillary dissection for breast cancer.
Trial registration number: NCT01116713
Background
Breast cancer is the most frequent malignant neoplasm
worldwide. In emerging countries such as Mexico, there
has been an increase in its frequency and mortality [1,2]
and it is the second most frequent neoplasm after cervi-
cal carcinoma. Between 25,000 and 30,000 new cases are
diagnosed annually. Unfortunately, only a few women
have regular mammography screening so the proportion
of patients with locally advanced disease at diagnosis is
high. In 2003, only 5-10% of newly diagnosed cases in
Mexico were clinical stages 0 or I [2]. Surgical resection
with axillary lymph node dissection constitutes the
treatment of choice associated with neoadjuvant therapy
and postoperative chemotherapy and/or radiation
therapy.
Postoperative nausea and vomiting (PONV) are the
most common complications after anesthesia and
surgery [3,4]. Women undergoing mastectomy with axil-
lary dissection are at a particularly high risk for the
development of PONV and an incidence of 60-80% in
patients receiving no antiemetic has been reported [5-7].
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tents, wound dehiscence, psychological distress, and
delayed recovery and discharge times [3]. These justify
the use of prophylactic antiemetics in women scheduled
for mastectomy. Most of the currently used antiemetics,
including antihistamines, butyrophenones and dopamine
receptor antagonists have been reported to cause occa-
sional undesirable adverse effects, such as excessive
sedation, hypotension, dry mouth, dysphoria, hallucina-
tions and extrapyramidal signs [3]. Antiserotonins (e.g.,
ondansetron) are available for the prevention and treat-
ment of PONV in patients undergoing various types of
surgery [4]. However, the use of prophylactic antiemetic
therapy with antiserotonins has been criticized for being
too expensive [8,9].
Dexamethasone was first reported to be an effective
antiemetic regimen in patients receiving cancer che-
motherapy [10]. Holte et al. [11] have reviewed the
available randomized trials (1996-2001) regarding perio-
perative single-dose steroid administration and found
that dexamethasone had antiemetic and analgesic effects
in various types of operations. Wattwil et al. [12]
showed that dexamethasone at 4 mg was effective for
the prevention of PONV following breast surgery but
they could not demonstrate any difference in postopera-
tive pain.
The purpose of this study was to evaluate the efficacy
of dexamethasone treatment for reducing pain and
PONV as well as analgesic and antiemetic requirements
in women undergoing general anesthesia for mastect-
omy with axillary lymph node dissection.
Methods
Patients
Between June and August 2009, 70 patients undergoing
mastectomy with axillary dissection were studied in a
prospective, randomized, double-blind clinical trial.
Patients were randomized to receive intravenous dexa-
methasone (8 mg) or homologated placebo 60 minutes
before skin incision, using an equal number of blinded
envelopes. Patients of American Society of Anesthesiolo-
gists classes III and IV were excluded. Further exclusion
criteria were age more than 80 years; pregnancy; active
menstruation; treatment with steroids; severe diabetes
mellitus (serum HbA1c > 8%); use of opioids, sedatives
or any kind of analgesics less than one week before mas-
tectomy, or a history of alcohol or drug abuse. Patients
with any history of motion sickness and/or previous
PONV after any surgical procedure were excluded. All
patients were admitted to the hospital one day before
the operation and were followed from hospital admis-
sion until 30 days after the surgical procedure to detect
any medical or surgical morbidity.
Anesthesia and surgery
All patients underwent a standardized general anesthesia
procedure and none of them received any preanesthetic
medication. Induction used intravenous propofol
(2 mg/kg body weight) and fentanyl (3-5 μg/kg). Vecur-
onium bromide (0.1 mg/kg) was used to facilitate
tracheal intubation. Anesthesia was maintained with
2-3% sevoflurane and 66% nitrous oxide in oxygen. Ven-
tilation was controlled mechanically and maintained
constant throughout surgery using an anesthetic and
respiratory gas analyzer for monitoring.
All patients were monitored with indirect determina-
tions of arterial pressure and heart rate using standard
techniques, as well as the expired CO2 content and oxy-
gen blood saturation. Afterwards, all patients were extu-
bated and transferred to the immediate postsurgical care
unit with cardiovascular and oxygen monitoring.
Surgical procedures
All patients were treated according to the preoperative
clinical stage with radical mastectomy or breast conser-
vative surgery with lymph node axillary dissection by
the same surgical team. In all patients, closed suction
drains were placed in the region subjected to surgery
and were removed during the following days. Che-
motherapy and/or radiotherapy were administered 3-4
weeks after uncomplicated surgical resections.
Analgesia and antiemetic therapies
Pain was assessed immediately on return to the recovery
room and at 6, 12 and 24 h after the operation using a
visual analogue scale (VAS; 0 = no pain to 10 = most
severe pain). Analgesia was given as intravenous sodium
ketorolac (30 mg every 8 hours) and intravenous trama-
dol infusion (50 mg) was used as a backup analgesic
medication. The incidence of PONV was recorded
immediately on return to the recovery room and at 6,
12 and 24 h after the operation, using a three point
ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =
vomiting). Nausea was defined as a subjectively unplea-
sant sensation associated with awareness of the urge to
vomit, retching was defined as the labored, spasmodic,
rhythmic contraction of the respiratory muscles without
the expulsion of gastric contents, and vomiting was
defined as the forceful expulsion of gastric contents
from the mouth. Intravenous ondasetron (4-8 mg) was
given for antiemetic treatment on demand.
Data collection and statistical analysis
Postoperative complications were recorded during hos-
pitalization and the patients were followed up to 30
days after discharge. Additional data collected included
patient age, body mass index (BMI), any history of
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operation time and the frequency of use of analgesic
and antiemetic drugs. These parameters were summed
and compared between the dexamethasone and placebo
groups. The study endpoints were postoperative nausea
and vomiting, and pain measured by the VAS and the
need for additional analgesic and antiemetic drugs.
The sample size was predetermined. We expected a 35
percent point difference in the incidence of nausea and
vomiting between groups favoring dexamethasone use.
The a e r r o rw a ss e ta t0 . 0 5a n db error at 0.20; n =3 5
patients for each group was considered adequate,
according to a power analysis. Results are expressed as
percentages and as the mean ± standard deviation (SD).
Student’s t test, and Fisher’sE x a c tT e s tw e r eu s e df o r
the analysis of quantitative and qualitative data, respec-
tively. Two-sided tests were used to declare statistical
significance at p < 0.05.
Ethical considerations
The study was conducted according to the principles of
the Declaration of Helsinki of 1989 and the Mexican
Health Guidelines. The Ethical and Research Commit-
tees of the Oncologic Institute of Jalisco, Mexico
approved all protocols. Full, written informed consent
was obtained from all patients before their inclusion in
the study.
Results
There were no significant differences between the two
groups with regard to mean age, weight, height, BMI,
neoadjuvant chemotherapy, type of surgical procedure,
length of surgical procedures, length of anesthesia or
operative bleeding (Table 1). Figure 1 shows the median
VAS values for pain. Dexamethasone significantly
reduced postoperative pain just after surgery (VAS
score, 4.54 ± 1.55 vs.5 . 8 3±2 . 0 0 ;p = 0.004), 6 h after
the operation (VAS score, 3.03 ± 1.20 vs. 4.17 ± 1.24;
p < 0.0005) and 12 h after the breast surgery (VAS
score, 2.09 ± 0.85 vs. 2.54 ± 0.98; p =0 . 0 4 ) .N od i f f e r -
ence was observed 24 h after the operation (1.23 ± 0.42
vs.1.43 ± 0.55; p = 0.09). Analgesics were required in
more patients of the control group than in the dexa-
methasone group (21 vs.1 0 ;p = 0.008). The mean dose
of intravenous tramadol was lower in the study group
(36.01 ± 12.62 vs. 55.74 ± 27.36; p = 0.03).
The incidence of PONV is described in Table 2. There
were significant differences between the two groups in
terms of the early postoperative evaluation in the recov-
ery room and at 6 h, favoring the dexamethasone group.
More patients in the placebo group required the admin-
istration of additional antiemetics (21 vs.8 ;p = 0.01);
the mean dose of ondansetron was 7.05 ± 2.80 mg in
the control group and 4.50 ± 1.41 mg in the study
group (p = 0.02).
The hospital stay was 1-3 days. No morbidity was
observed during the follow up period. Drains were
removed when the fluid output was less than 50 ml/24
h. One patient in the control group developed a general-
ized rash before the skin incision was started.
The adverse event was treated with intravenous antihis-
taminic and hydrocortisone with complete resolution.
Table 1 Baseline characteristics of the patients in the study and the placebo groups
Placebo group
(n = 35)
Dexamethasone group (n = 35)
Age (years)
a 49.89 ± 10.58 50.11 ± 12.37
Weight (kg)
a 67.94 ± 9.91 69.52 ± 13.63
Height (cm)
a 158.14 ± 6.33 157.31 ± 6.57
Body mass index
a 27.20 ± 4.29 28.20 ± 6.38
Normal weight 20-25 (%) 11 (31.4%) 12 (34.3%)
Overweight 25.1-29.9 (%) 15 (42.9%) 14 (40%)
Obesity grade I 30-34.9 (%) 7 (20%) 5 (14.3%)
Obesity grade II 35-39.9 (%) 2 (5.7%) 2 (5.7%)
Obesity grade III >40 (%) 0 2 (5.7%)
Smoking (%) 2 (5.7%) 4 (11.4%)
Neoadjuvant chemotherapy (%) 13 (37.1%) 15 (42.8%)
Surgical procedure
Radical mastectomy + axillary dissection (%) 32 (91.4%) 34 (97.1%)
Quadrantectomy + axillary dissection (%) 3 (8.6%) 1 (2.9%)
Surgery time (min)
a 119.42 ± 26.97 120.54 ± 30.34
Length of anesthesia (min)
a 140.71 ± 26.76 139.60 ± 34.56
Bleeding (ml)
a 165.85 ± 61.10 156.85 ± 60.11
aValues are expressed as the mean ± standard deviation.
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didate. There was no mortality.
Discussion
In this randomized, double-blind, placebo-controlled
study, preoperative dexamethasone (8 mg) significantly
reduced the incidence of pain, PONV and analgesic and
antiemetic requirements after breast surgery for cancer.
PONV is an unpleasant, distressing and exhausting
complication for patients. It can prolong recovery time,
delay patient discharge and increase hospital costs [13].
T h ee t i o l o g yo fP O N Va f t e rb r e a s ts u r g e r yi sn o t
entirely clear. Factors affecting PONV after breast sur-
gery are those related to the patients, those related to
the surgical procedure and the anesthetic technique and
the postoperative care [14]. Risk-scoring systems have
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Figure 1 Pain VAS score of patients in the control and study groups.
Table 2 Incidence of PONV in the dexamethasone and placebo groups
Placebo group (n = 35) Dexamethasone group (n = 35) P
In recovery room:
➢ PONV 21 (60%) 10 (28.6%) 0.02
➢ Asymptomatic 14 (40%) 25 (71.4%)
6 h after surgery:
➢ PONV 16 (45.8%) 6 (17.2%) 0.03
➢ Asymptomatic 19 (54.2%) 29 (82.8%)
12 h after surgery:
➢ PONV 6 (11.2%) 4 (11.5%) 0.35
➢ Asymptomatic 29 (82.8%) 31 (88.5%)
24 h after surgery:
➢ PONV 5 (14.3%) 1 (2.9%) 0.23
➢ Asymptomatic 30 (85.7%) 34 (97.1%)
PONV, postoperative nausea and vomiting.
p values calculated using two-sided Fisher’s Exact Test.
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select patients for prophylaxis against PONV [15,16].
Complicated formulations were simplified establishing
four predictor factors: a) female sex; b) a history of
motion sickness and/or PONV; c) absence of a smoking
habit and d) any use of opioids [17]. If none, one, two,
three or four of these factors were present, the incidence
of PONV was 10%, 23%, 39%, 61% and 79% respectively
[17]. Breast surgery inherently caters to high-risk
patients and being female was an independent predictor
for PONV in multivariate analysis [15,16]. In our study
patients with history of motion sickness and/or PONV
were not included and only a few of our patients were
active smokers. The first condition lowers the threshold
for vomiting [18] and smoking provides some protection
against it [3]. The length of the surgical procedure also
increases the risk of PONV. As established by Sinclair
et al. [16], each 30 min increase in the duration of sur-
gery increases the incidence of PONV by 60%. Anes-
thetic-related factors have a strong influence on the
incidence of PONV because the use of opioids as pre-
medications or to maintain anesthesia stimulates central
nervous system (CNS) opioid receptors [19]. Nitrous
oxide causes PONV by stimulating the CNS with cate-
cholamine release and changes in middle-air pressure
with subsequent stimulation of the vestibular system
and elevation of abdominal pressure as a consequence
of the exchange of nitrous oxide and nitrogen in gas
introduced into the gastrointestinal tract during mask
ventilation [20-24]. The use of propofol for maintaining
anesthesia has a positive effect on reducing PONV [25].
Postoperatively, the administration of opioids might
contribute to these episodes [26].
Since the original description of dexamethasone as an
effective antiemetic drug [10], studies have reported it
to be effective for the prevention of nausea and vomit-
ing after different surgical procedures. The biological
action of a glucocorticoid begins 1-2 h after administra-
tion [27]. The antiemetic mechanism of dexamethasone
is not known. However, central inhibition of prostaglan-
din synthesis, inhibition of endogenous opioid release
and changes in the permeability of the blood-brain bar-
rier to serum proteins have been suggested [27,28]. The
analgesic effects of glucocorticoids are mainly provided
through the peripheral inhibition of phospholipase,
thereby decreasing the products of the cyclooxygenase
and lipoxygenase pathways in the inflammatory
response [29].
In this trial, a variety of risk factors were present in
both groups of patients. This included being female,
nonsmoking, receiving neoadjuvant chemotherapy,
undergoing an operative procedure and anesthesia, the
presence of postoperative pain and the use of opioids.
All of these factors are considered to affect the
incidence of PONV; however, they were well balanced
between the placebo and dexamethasone treatment
groups. Therefore, the difference in the rate of patients
experiencing PONV among the groups can be attributed
to the use of dexamethasone.
Our results are similar to those reported by Fujii and
Nakayama [30]. They designed a randomized clinical
trial with 90 patients submitted to breast surgery (24%
of them treated without axillary lymph node dissec-
tion). They divided the patients into three groups
of 30. Patients received intravenous dexamethasone at
doses of 4 or 8 mg preoperatively and the control
group received placebo. They evaluated the incidence
of PONV and analgesic requirements until 24 h after
the surgical procedure. The incidence of PONV was
67% in the placebo group versus 33% and 27% in the 4
mg and 8 mg dexamethasone groups (p =0 . 0 1a n d
0.002, respectively). The need for rectally administered
indomethacin for relieving intolerable pain was less in
patients who had received 8 mg dexamethasone than
in those who received placebo (p = 0.001) or dexa-
methasone at 4 mg (p = 0.034). No difference in
analgesic requirement was found between the 4 mg
dexamethasone and placebo groups (p =0 . 1 8 ) .T h e y
concluded that dexamethasone at 8 mg effectively
decreased PONV and analgesic requirements in
women undergoing general anesthesia.
Conclusions
Our results suggest that preoperative dexamethasone at
8 mg ameliorates nausea, vomiting, pain and reduces
the analgesic and antiemetic requirements of women
after breast surgery for cancer without apparent side
effects. It appears to be a valuable treatment for pre-
venting such adverse postoperative symptoms.
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